WHO Flags Counterfeit DARZALEX Detected in Maldives and Mexico Supply Chains

Counterfeit units of DARZALEX (daratumumab), Johnson & Johnson's CD38-targeting biologic for multiple myeloma, have been confirmed in the supply chains of two geographically separate markets, signalling a serialization and distribution integrity risk that QA and supply chain leads in emerging-market operations cannot treat as isolated incidents.

The World Health Organization issued a medical product alert after national regulatory authorities in the Maldives and Mexico independently reported the falsified product in May and June 2026, respectively. The dual-jurisdiction detection pattern suggests the counterfeit network is operating across more than one distribution corridor, raising the probability of further undisclosed exposure in markets with less mature pharmacovigilance infrastructure.

For QA directors, the immediate compliance read centres on supply chain traceability. DARZALEX is a high-value injectable biologic administered in oncology settings, where a falsified product carries direct patient safety consequences beyond the regulatory exposure. Verification protocols at the point of receipt, including serialization checks and cold-chain documentation review, become the first line of defence where secondary market sourcing or parallel trade is a factor.

Regulatory affairs leads should note that WHO rapid alerts of this type typically precede intensified scrutiny from national authorities in adjacent markets. Facilities distributing or repackaging biologics in regions with developing track-and-trace infrastructure should review their 21 CFR Part 211 or equivalent GMP obligations around incoming material verification and supplier qualification, and confirm that deviation and CAPA records reflect current counterfeit-risk controls.

The incidents also carry implications for serialization programme maturity. Where markets lack mandatory unit-level serialization aligned with standards such as those under ICH Q10-compliant pharmaceutical quality systems, the burden of authenticity verification shifts upstream to the manufacturer and its authorised distributors. J&J has not publicly detailed the specific physical or chemical markers that distinguish the falsified units, making WHO's alert the primary reference document for procurement and QA teams conducting risk assessments.

The WHO alert remains the authoritative source for affected-lot details, and QA teams should confirm whether their current supplier qualification records and incoming inspection SOPs are adequate to the risk profile now documented across two markets.

Source: WHO via Media4Growth / Indian Pharma Post, 7 July 2026.